By Industry News
Miami, FL – June 10, 2021 – Amniox Medical, Inc. (Amniox), a TissueTech, Inc. company and pioneer in the clinical application of human birth tissue products, is launching a new awareness campaign that showcases the Amniox comprehensive family of human birth tissue-based products to facilitate wound healing and reduce associated cost of care. This year, Amniox commemorates ten years of improving patients’ lives by offering the natural potential of birth tissue products for surgical and wound applications to help expedite functional recovery.
The campaign – The Amniox Advantage – features evidence-based best practices while exploring the economic impact on the health care delivery system resulting from treating complex wounds. In one study published by the Alliance of Wound Care Stakeholders, researchers found that chronic non-healing wounds impact nearly 15% of Medicare beneficiaries (8.2 million) with an estimated annual cost is $28 billion.1
“We are proud to support all of the members of the American Board of Wound Management and acknowledge all that they do to promote wound care – especially during Wound Healing Awareness Month,” said Herbert Slade, MD, Chief Medical Officer, TissueTech, Inc.
Amniox is committed to addressing unmet patient clinical needs, as illustrated in a clinical case study using NEOX® CORD 1K as an adjunct therapy to treat necrotizing fasciitis, a severe infection often involving the foot and ankle. This type of infection carries very high morbidity and mortality rate, frequently resulting in amputation. In honor of Wound Care Awareness Month, Amniox has supplemented its website to showcase the Amniox Advantage campaign.
About Amniox Medical
AMNIOX® Medical, Inc. is the first provider of a cryopreserved matrix comprised of human umbilical cord that can be stored in a refrigerator for up to two years and is ready to use without thawing, transplanting the benefits of regenerative healing for non-healing and chronic wounds.
The views and opinions expressed in this blog are solely those of the author, and do not represent the views of WoundSource, Kestrel Health Information, Inc., its affiliates, or subsidiary companies.